来源：Gangtise投研

　　微创脑科学（02172.HK）2024年年度业绩发布会：2024年，本集团营收达7.62亿元，同比增长14%，净利润2.49亿元，增长85%，经调整净利润年复合增长率约55%。海外收入7500万元，增长138%。国内市场市占率第三，国际市场超一家国际公司。新增450家医院，覆盖3700家，支持21万台神经介入手术。8款产品出海，覆盖30个海外国家，国际业务首次盈利。拥有多个首创产品，如全球首款颅内覆膜支架等。9款新产品上市，预计新一代带涂层密网支架明年获批，可降解弹簧圈两年内上市。弹簧圈占出海销售额80%，牛门秀可弹簧圈受国际医生青睐，预计带来较大销售增长。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：王若云

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.